Literature DB >> 24552411

Levamisole-induced myopathy and leukocytoclastic vasculitis: a case report and literature review.

Meng-Hsuan Tsai1, Jen-Hung Yang, Sheng-Ling Kung, Yu-Ping Hsiao.   

Abstract

Levamisole, an immunomodulator and anthelmintic medication, has been used in dermatology for years. Even though the adverse effects are usually mild and reversible, attention should be paid toward severe events such as vasculitis and neutropenia. To the best of our knowledge, this is the first case report on a patient presenting with myopathy caused by levamisole. Here, we report a 34-year-old woman with recalcitrant warts who received levamisole 100 mg daily for 5 days. Subsequently, bilateral lower limb weakness accompanied by multiple painful and non-blanchable purpura was noted. Levamisole-induced myopathy and leukocytoclastic vasculitis were diagnosed by skin histopathology, direct immunofluorescence, and electromyography. After discontinuing levamisole and giving a short course of systemic steroid, these symptoms demonstrated a resolving trend.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  leukocytoclastic vasculitis; levamisole; myopathy

Mesh:

Substances:

Year:  2013        PMID: 24552411     DOI: 10.1111/dth.12018

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  3 in total

1.  Leukocytoclastic vasculitis drug reaction to certolizumab pegol.

Authors:  Meghan Woody; Donald Warren; Laura Speck; Julie Jackson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

2.  Nafcillin implicated in a case of cutaneous and gastrointestinal leukocytoclastic vasculitis.

Authors:  Changqing Xie; Suchita S Pancholi; Niti Armistead
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 3.  Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.

Authors:  Rafael G Grau
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.